**Summary**
RTW Biotech Opportunities Ltd released its monthly valuation update and factsheet for January 2026, highlighting key financial and operational developments. As of December 31, 2025, the company’s unaudited net asset value (NAV) per share was $2.45, a 4.2% decrease from the previous month, underperforming the Nasdaq Biotech Index (-1.9%) but outpacing the Russell 2000 Biotech Index (+0.5%). Since its launch in October 2019, the company has delivered an annualized NAV return of 14.5%.
**Portfolio Highlights**
Top holdings include PTC Therapeutics (11.6% of NAV), Corxel (6.2%), and Stoke Therapeutics (5.2%).
Top contributors to NAV in the period were Avidity (+9.5%), PTC (+5.1%), and Stoke (+4.9%), while detractors included Rocket (-3.9%) and Artios (-2.9%).
**Company Updates**
The company allocated an additional $15 million to NAV-accretive share buybacks, supplementing the existing $30 million program, following successful M&A transactions.
RTW Biotech was included in the FTSE 250 Index in December 2025, enhancing liquidity and investor awareness.
The company hosted its first retail shareholder webinar in December, presented by its chair and RTW Investments executives.
**Performance and Sector Outlook**
In Q4 2025, the company’s NAV returned +15.5%, underperforming the Russell 2000 Biotech Index (+29%) and Nasdaq Biotech Index (+17%).
The biotech sector rebounded in 2025, with indices outperforming the S&P 500 and Nasdaq, driven by reduced policy uncertainty, increased M&A activity ($105B in deals), and improved investor sentiment.
RTW Biotech remains optimistic for 2026, citing continued innovation, a strong financing environment, and further M&A opportunities.
**Recent Investment**
In December 2025, the company invested $5.9 million in Yarrow Bioscience, a clinical-stage biotech focused on autoimmune thyroid diseases, representing 0.7% of NAV. Yarrow is set to merge with VYNE Therapeutics in Q2 2026.
**Conclusion**
RTW Biotech Opportunities Ltd continues to focus on long-term capital growth, leveraging its expertise in the biopharmaceutical and medical technology sectors. Despite short-term NAV fluctuations, the company remains well-positioned to capitalize on the biotech sector’s recovery and emerging opportunities.